Finland· FI-REL-REL503

Vicks Formula 44

A opium-derivate und expektoranzien product containing noscapine hydrochloride + guaifenesin, registered in Finland by Procter & Gamble (Health & Beauty Care) Limited. The same ATC class is registered in 5 of our 19 countries.

ATC R05FA02

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedVicks Formula 44ATCR05FA02REGISTER NO.FI-REL-REL503PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Opium-derivate und expektoranzien is registered in 5 of 19 countries.

Countries holding a registration under ATC R05FA02 (opium-derivate und expektoranzien), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 4 of them publish a price we can compare per daily dose

Opium-derivate und expektoranzien · ATC R05FA02

5 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Norwayprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Noscapine hydrochloride + Guaifenesin
Manufacturer
Procter & Gamble (Health & Beauty Care) Limited
Country
Finland (FI)
ATC code
R05FA02
ATC class
Opium-Derivate und Expektoranzien
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Opium-derivate und expektoranzien in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All opium-derivate und expektoranzien products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Austria · Tuscalman
  • Belgium · Noscaflex Expectorans

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0fa2a64b-3c5d-4361-8940-09964f15ef0d
GET /v1/drugs/0fa2a64b-3c5d-4361-8940-09964f15ef0d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "9",
  "form": "mikstuura",
  "route": null,
  "ddd_unit": "ED",
  "strength": null,
  "atc_label": "opiumjohdokset ja ekspektorantit, lukuun ottamatta mukolyyttejä",
  "ma_number": "4621",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL503",
  "authorised_at": "1967-03-29"
}

See everything about opium-derivate und expektoranzien.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.